L.A. is particularly susceptible to “miracle” cures. And there are some troubling aspects of the Ozempic gold rush that don’t ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in an early victory for the pharma companies ...

GSK did not admit wrongdoing as part of the deal, saying in a statement that there was "no consistent or reliable evidence" that ranitidine, the drug's active ingredient, increased the risk of cancer.

GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British ...

A Chicago jury failed to reach a verdict Sept. 18 over claims that heartburn drug Zantac causes cancer, Reuters exclusively reported. The case, brought by Illinois resident Ronald Kimbrow ...

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

GlaxoSmithKline agreed on Sept. 17 to settle out of the first Zantac trial in California, which began this month in Oakland. GSK won two defense verdicts in Illinois earlier this year but faced ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked companies producing Zantac to remove all ranitidine-based drugs from the U ...